University of Wollongong

Research Online
Faculty of Engineering and Information Sciences Papers: Part A

Faculty of Engineering and Information Sciences

2016

Optimizing dose enhancement with Ta2O5
nanoparticles for synchrotron microbeam activated
radiation therapy
Elette Engels
University of Wollongong, ee215@uowmail.edu.au

Stephanie Corde
University of Wollongong, scorde@uow.edu.au

Sally McKinnon
University of Wollongong, srm286@uowmail.edu.au

Sebastien Incerti
Universite Bordeaux I, incerti@cenbg.in2p3.fr

Konstantin K. Konstantinov
University of Wollongong, konstan@uow.edu.au
See next page for additional authors

Publication Details
Engels, E., Corde, S., McKinnon, S., Incerti, S., Konstantinov, K., Rozenfeld, A., Tehei, M., Lerch, M. & Guatelli, S. (2016). Optimizing
dose enhancement with Ta2O5 nanoparticles for synchrotron microbeam activated radiation therapy. Physica Medica: an
international journal devoted to the applications of physics to medicine and biology, 32 (12), 1852-1861.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

Optimizing dose enhancement with Ta2O5 nanoparticles for synchrotron
microbeam activated radiation therapy
Abstract

Microbeam Radiation Therapy (MRT) exploits tumour selectivity and normal tissue sparing with spatially
fractionated kilovoltage X-ray microbeams through the dose volume effect. Experimental measurements with
Ta2O5 nanoparticles (NPs) in 9L gliosarcoma treated with MRT at the Australian Synchrotron, increased the
treatment efficiency. Ta2O5 NPs were observed to form shells around cell nuclei which may be the reason for
their efficiency in MRT. In this article, our experimental observation of NP shell formation is the basis of a
Geant4 radiation transport study to characterise dose enhancement by Ta2O5 NPs in MRT. Our study
showed that NP shells enhance the physical dose depending microbeam energy and their location relative to a
single microbeam. For monochromatic microbeam energies below ∼70 keV, NP shells show highly localised
dose enhancement due to the short range of associated secondary electrons. Low microbeam energies indicate
better targeted treatment by allowing higher microbeam doses to be administered to tumours and better
exploit the spatial fractionation related selectivity observed with MRT. For microbeam energies above ∼100
keV, NP shells extend the physical dose enhancement due to longer-range secondary electrons. Again, with
NPs selectively internalised, the local effectiveness of MRT is expected to increase in the tumour. Dose
enhancement produced by the shell aggregate varied more significantly in the cell population, depending on
its location, when compared to a homogeneous NP distribution. These combined simulation and
experimental data provide first evidence for optimising MRT through the incorporation of newly observed
Ta2O5 NP distributions within 9L cancer cells.
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Abstract
Microbeam Radiation Therapy (MRT) exploits tumour selectivity and normal tissue sparing with
spatially fractionated kilovoltage X-ray microbeams through the dose volume effect. Experimental
measurements with Ta2O5 nanoparticles (NPs) in 9L gliosarcoma treated with MRT at the
Australian Synchrotron, increased the treatment efficiency. Ta2O5 NPs were observed to form
shells around cell nuclei which may be the reason for their efficiency in MRT. In this article, our
experimental observation of NP shell formation is the basis of a Geant4 radiation transport study to
characterise dose enhancement by Ta2O5 NPs in MRT. Our study showed that NP shells enhance
the physical dose depending microbeam energy and their location relative to a single microbeam.
For monochromatic microbeam energies below ~ 70 keV, NP shells show highly localised dose
enhancement due to the short range of associated secondary electrons. Low microbeam energies
indicate better targeted treatment by allowing higher microbeam doses to be administered to
tumours and better exploit the spatial fractionation related selectivity observed with MRT. For
microbeam energies above ~ 100 keV, NP shells extend the physical dose enhancement due to
longer-range secondary electrons. Again, with NPs selectively internalised, the local effectiveness of
MRT is expected to increase in the tumour. Dose enhancement produced by the shell aggregate
varied more significantly in the cell population, depending on its location, when compared to a
homogeneous NP distribution. These combined simulation and experimental data provide first
evidence for optimising MRT through the incorporation of newly observed Ta2O5 NP distributions
within 9L cancer cells.
Keywords: nanoparticle, microbeam radiation therapy, dose enhancement, Geant4.

1. Introduction
Cancer remains one of the leading causes of death worldwide. Amongst other treatment methods, such as
surgery and chemotherapy, the use of radiation in the treatment of cancer remains the most prominent and
successful modality [1]. The sensitive treatment of brain tumours (such as inoperable gliomas and
gliosarcomas), with wide, and unsegmented radiotherapeutic beams, impart unavoidable yet clinically
unacceptable damage to vital central nervous system (CNS) tissues [2,3]. Microbeam radiation therapy
(MRT) may provide a solution to this challenge.

MRT involves the application of an array of spatially fractionated microbeams sourced from third
generation synchrotrons, with beam widths ranging from 25 to 75 µm, and a pitch of 200-400 µm [2-15].
The energy of these beams lie within the kilovoltage X-ray range of 50-175 keV, as first outlined by
Slatkin et al. [4]. Microbeam peak doses of between 500-1000 Gy can be delivered safely due to the wellknown dose volume effect [5-8].

The treatment quality of MRT is assessed by the peak-to-valley dose ratio (PVDR), which describes the
ratio between the in-beam dose to the out-of-beam dose at mid distance between two adjacent
microbeams. The peak doses are typically 20-100 times higher than the valley [5,6,7]. Small PVDRs
indicate that the valley dose between adjacent microbeams, is large in relation to the peak dose. When
made comparable to the large peak doses, this indicates better tumour coverage [7,8]. Conversely, a large
PVDR and small valley dose may be more accommodating for tissue recovery, allowing normal tissue to
be spared through the dose-volume effect [5-8].

The key advantage of MRT arises from the reported increase in sensitivity of tumour tissue to the
microbeam array, which differs to the observed recovery of normal tissue [9-17]. Radiation treatments
for radioresistant tumours such as gliomas, require extremely high absorbed doses [15,16], yet with their
development in sensitive brain tissue, large doses cannot be administered without significant damage.
MRT becomes a preferable option as tumour control is maintained, and normal tissue can withstand high
radiation doses when delivered in small volumes [9,10]. Some pre-clinical trials note the development of
minor cerebral oedemas following MRT [18]. However, the oedemas disappear within a week after the
MRT treatment, in agreement with studies that highlight the success of normal tissue sparing with MRT
[9-17].

The effectiveness of MRT as a selective cancer treatment is yet to be understood completely.
Radioresistant brain tumours, such as 9L gliosarcoma, are seen to be more effectively treated with MRT
than broad beams due to large peak doses [15,16]. Crosbie et al. [11], indicates that there is a significant
difference in the migration of tumour cells in comparison to the normal cells. This may increase the
probability of cellular communications to initiate widespread apoptosis [12,14]. This, and extreme
damage to local tumour vasculature [13], may provide a reason for the success of spatially fractionated
beams to control radioresistant tumours. Therefore, the future applications of MRT are aimed at treating
brain tumours. There is good prognosis for child brain cancers, with less risk of damage to the developing
CNS than conventional broad beams [18].

High-Z nanoparticles (NPs) have been shown to improve the effectiveness of dose conformity to tumour
tissue in the case of conventional unsegmented kilovoltage X-rays [19-30]. The advantages of NPs,
besides the primary benefit of enhancing tumour radiosensitivity, often include biocompatibility,
permeability to cell membranes due to their nano-scale dimensions, ability to specifically target certain
tumours when coated and actively accumulate at tumour sites with leaky vasculature [21,22].

In MRT, NPs may be useful by raising the local dose to the tumour, in particular to enhance the low
valley dose at the site of the tumour [7]. NP use may in turn promote more normal tissue sparing, as peak
doses could be lowered to induce the same clinical treatment outcome.

This potential has been

demonstrated by Rahman et al. [27], showing that in the presence of gold NPs (GNPs), the necessary
dose delivered by MRT to kill endothelial cells can be reduced by 10 Gy. Martínez-Rovira et al. [7]
demonstrated through Geant4 simulations, that GNPs enhanced the valley dose and produce signiﬁcant
decreases in the PVDR at the site of the tumour. This translates in a reduced dose in the healthy tissue,
limiting possible collateral effects.

Tantalum pentoxide (Ta2O5) NPs are a non-toxic, nano-structured ceramic compound. Their use as a
radiosensitizer was first reported by Brown et al. [28] in conventional X-ray radiotherapy. These nanostructured ceramic particles have different aggregation properties than inert metal NPs. In particular, they
tend to form shell aggregates instead of distributing homogeneously in the medium, producing different
physical dose enhancements [29].

Geant4 simulations were performed by McKinnon et al. [29] to characterise the physical dose
enhancement produced by different distributions of Ta2O5, as observed experimentally, for a 150 kVp
broad beam. The shell structures produced large localised physical dose enhancements to surrounding

cells using the kV broad beam, with large NP clusters up to 7 µm thick producing dose enhancement that
is up to 100 times.

Because of the promising outcome obtained for conventional kV radiotherapy, Ta2O5 NPs have great
potential to enhance the clinical outcome of MRT. This article shows a Geant4 simulation study aimed to
determine how the physical dose in MRT treatments can be optimised in a cell population with Ta2O5
NPs. The use of NPs in MRT is a novel multi-modal approach named Synchrotron Microbeam Activated
Radiation Therapy (SMART). This work was motivated by new experimental findings of our first cell
survival experiments produced at the IMBL beamline of the Australian Synchrotron.

2. Motivation of the Geant4 simulation study: Experimental Measurements
This section summarises the first experimental measurements performed at the IMBL beamline of the
Australian Synchrotron (AS) with tumorous 9L gliosarcoma cells and Ta2O5 nanoparticles, motivating the
Geant4 simulation study of this work. The details of the radiobiological experiments will be object of a
separate article.

Ta2O5 NPs are nano-structured ceramic particles that have shown to enhance conventional kV and MV
radiotherapy [29,30]. Ta2O5 NPs are manufactured according to Brown et al. [28] and added to the cell
culture flask to incubate for 24 hours. The toxicity to the cells with concentrations of 50-500 µg/mL, after
24 hrs incubation, was found to be very low, with cell clonogenic survival of 80-100% [28,30]. Therefore,
there is no lethality towards cells besides that induced due to ionising radiation.

Besides this low-toxicity, Ta2O5 NPs show great promise for treatments of these radio-resistant
gliosarcomas, due to their inherent ability to internalise for long periods of time in 9L gliosarcoma. Figure
2.1 demonstrates the results of a series of images of the 9L gliosarcoma cells taken after 15 hrs of
incubation with Ta2O5 at the AS.

Cell membrane
Nucleus

Ta2O5 NPs

Figure 2.1 Observed Ta2O5 NPs internalisation in experimental studies with 9L gliosarcoma cells:
Clusters of nanoparticles (red) and smaller aggregates (green) are encompassed by the 9L cells (0.5 hr)
and transported toward the cell nucleus (2-4 hrs) to form a clustering shell (these times are after 15hrs
incubation). Flask NP concentration was 200 µg/mL.
NPs are allowed into cells (endocytosis mechanisms, in particular phagocytosis, [26]), where they begin
to aggregate with other clusters of Ta2O5. With the observation of these NPs forming “shells” around 9L
tumour cell nuclei, it was decided to investigate their efficacy in SMART and how dose enhancement is
impacted by the NPs distribution considerations.
For experimental studies, T12.5cm2 flasks with/without NPs were irradiated in a vertical orientation at AS
IMBL hutch 1B, with a single dose (0.4 Gy in the valley), with a dose rate of 500 Gy/s in the peak, and
average beam energy of 90 keV. MRT beams were 25 µm and 50 µm wide and pitch of 200 µm centre to
centre Fig. 2.2 shows the normalised cell survival fraction in 9L cells with increasing NP concentrations
in the flask. The results show that Ta2O5 NPs reduce the cell survival fraction in 9L cell lines irradiated
with MRT.

The physical dose enhancement due to NPs in a spatially fractionated and low energy radiation field may
vary due to NP distribution, for the case of Ta2O5 NP shells in particular. For this reason, our Geant4
simulation study aims to characterise what effect various sizes and positions the NP shells have on the
SMART effectiveness. The results obtained with NP shell congregates are compared to a homogeneous
solution of the same NP mass. The goal is to provide an insight into the physics behind the experimental
measurements, and indicate optimal conditions in terms of MRT beam energy. These outcomes identify

with a lower PVDR in the tumour and a higher PVDR in normal tissue [7,8], to maximise clinical
benefits.

Figure 2.2: Cell clonogenic survival fraction for 9L gliosarcoma cell line, exposed to 50 µm wide
microbeams with 200 µm pitch, at 0.4 Gy in the valley, with 50 and 500 µg/mL concentrations of Ta2O5
NPs. Normalisation was done to the non-irradiated control.

3. Methodology: The Geant4 simulation study
Monte Carlo simulations were performed using Geant4, version 10.1 [31, 32]. The simulation set-up,
shown in Fig. 3.1, consists of a water microscopic phantom (called here µ-phantom) with size 220 µm x
70 µm x 40 µm. A mono-layer of cell nuclei, modelled as 8 μm diameter spheres of water, were included
in the µ-phantom. The cell nuclei are 14 μm apart centre to centre, except in the penumbral region of the
cell population, where the nuclei are 16 μm apart (between S5 and S6 in Fig.3.1 and 3.2).
The µ-phantom was set normally to the beam direction, at 6 mm depth in a larger water phantom with 30
cm side lengths and 10.6 cm length in the direction of incidence of the beam. A 50 µm wide microbeam
was incident on the centre of the µ-phantom, with monochromatic energy spanning from 30 keV to 150
keV, which is a typical energy range used for realistic MRT beams. The case of a 50 µm wide photon
beam was considered, as it was the same width used in experimental studies.

In order to track secondary electrons down to 100 eV, and obtain shorter simulation execution times
compared to the Geant4-DNA Low Energy Extensions, the Low Energy Electromagnetic Physics models
based on PENELOPE [32-34] were adopted to describe particle interactions. Stewart et al. [33] showed
that PENELOPE physics models can estimate physical quantities on the micron-scale between 1 and 25%

agreement with track structure Monte Carlo codes when calculating the mean specific energy. Auger
electron emission and fluorescence are also modelled.
The physical dose enhancement in the cells of µ-phantom was studied by placing one shell-like Ta2O5 NP
congregate in different positions with respect to the incident microbeam and varying the energy of the
incident photon beam. Dose was calculated in individual cells.

When the NP congregate was set in the peak position (at S8 in Fig. 3.1), the dose was calculated by
doubling the statistics derived from the cells in symmetric positions, with respect to the axis of the
microbeam (corresponding to S1-S8 in Fig. 3.1). The NP congregate was then substituted by a
homogeneous solution of the same NP mass distributed in the water medium of µ-phantom, outside the
cells.

50 µm

Figure 3.1: Geant4 simulation set-up: the µ-phantom contains a cell (or cell nuclei) monolayer,
modelled with 75 spheres with 8 μm diameter. The cross-section of the µ-phantom traversed by the MRT
beam, the “peak region”, is indicated by the black rectangle. A side view of the monolayer is also shown
on the right with the beam in the z-direction. The MRT photon beam is incident along z-axis.
The Ta2O5 NP “shell” was modelled with thickness varying between 1 and 3 µm to reflect the average and
maximum shell cluster thicknesses observed in experimental studies. The corresponding local NP
concentrations in the µ-phantom, shown in Table 3.1, are consistent with the order of magnitude of the
concentrations of the experiments at the level of the cells, though only 1 shell is considered at a time.
Table 3.1 Calculated concentrations of NP and percentage mass of NP in water with respect to shell
thickness
Homogeneous solution
Shell structure
Local concentration of NPs in
Shell Thickness
% Mass of Ta2O5 NPs in the µthe volume of µ-phantom(mg/mL)
(μm)
phantom
1
0.34
3.4
2
0.84
8.5
3
1.53
15.6

The second study consisted of calculating the dose enhancement, moving the NP shell congregate from
the peak (position S8 in Fig. 3.2) to the valley. In particular, the NP shell congregate was moved from the
centre of the beam (P1) to the edge of the 50 µm beam (P2), the penumbral region (P3) and the valley
region (P4). In this case, a 3 µm NP shell was modelled, as it produces the greatest amount of secondary
electrons in photon interaction, due to its increased NP mass. In this set-up, the dose is calculated in each
cell of the monolayer and averaged over the cells along each line (S1, S2, up to S15, see Fig. 3.2), as there
is no symmetry with NP dose enhancement in this set-up.

Figure 3.2: Alternative positions of the NP shells in the µ-phantom.
The energy deposited in each cell was calculated and converted to dose per cell per incident photon, for
cases with Ta2O5 NPs in shells, homogeneous solution, or without Ta2O5 (water only). The physical dose
enhancement was evaluated with the dose enhancement ratio (DER), which is the ratio of the absorbed
dose per incident photon with Ta2O5 NPs present (DNP), to the absorbed dose in water without NPs (DW),
in the same irradiation conditions:
DER = DNP / DW.
The statistical uncertainty in the results obtained was determined by calculating the average and standard
deviation of multiple simulations with different simulation random seeds. Any additional uncertainty in
the simulation is a consequence of the uncertainty in physics models selected.

4. Results
4.1 Dose enhancement with the nanoparticle shell located in the microbeam peak
The first study quantified the DER (defined in section 3) of the NP shell when it is located in the MRT
peak (see Fig 3.1), and the energy of the incident microbeam is varied. The dose was integrated over the

peak region (indicated by a black rectangular contour in Fig. 3.1). Fig. 4.1 shows the DER with respect
to the energy of the incident monochromatic microbeam, and the effect of varying the NP shell
thickness.

Figure 4.1: Average DER w.r.t. beam energy with Ta2O5 NPs distributed as a shell around the central
cell, with varying shell thickness (see Table 3.1). Statistical uncertainty is present, though smaller than
plotted data points.
It can be observed that average DERs in the peak region range between 2 and 7 depending on microbeam
energy and NP shell thickness. The thicker the shell, the higher the average DER. Although, the relative
increase in DER is non-linear with respect to increasing shell thickness. Thicker shells produce more
secondary electrons in the NP, however, at the same time, the number of electrons escaping the NP
reduces because of the higher probability of ionisation interactions, which increase electron absorption in
the NP itself. The interplay between the two effects leads to an increase in DER, but the DER increase
becomes less efficient, eventually reaching a saturation effect as described in McKinnon et al. [29].

The optimum DER is produced for incident photon energies between 40 and 60 keV, depending on the
shell thickness. This energy correlates to a maximum in photon absorption relative to water for Ta2O5,
shown in Figure 4.2, which is dominant over the kV range.

The 67.4 keV K-edge [34] in Ta2O5 did not produce a larger DER. This occurs because at the K-edge
more electrons are produced in the NP, however the electrons reach the surrounding biological medium
with a relatively lower LET. Instead, for an incident 40-60 keV beam, there is an optimal combination
between the production cross section of secondary electrons in the NP, and their LET when reaching
cellular nuclei.

Figure 4.2: Ratio between the photon mass energy coefficients of Ta2O5 and water [34].

The dose in the entire µ-phantom was calculated with and without the NP shell set in the centre of the
beam, with a varying incident monochromatic energy between 50 keV and 150 keV. The Ta2O5 shell
thickness is varied between 1 and 3 μm. Fig 4.3 shows the results obtained for the lowest and highest
energy of the incident photon beam, 50 keV and 150 keV, respectively.
It can be observed that the presence of a NP shell produces long-range dose enhancement depending on
the energy of the photon beam. The peak dose is best enhanced for 50 keV photons (see Fig. 4.1) due to

(A)

(B)

Figure 4.3: Dose per incident photon calculated in the cell nuclei of the µ-phantom, with respect to the
distance from the beam centre. (A): The energy of the incident photon beam is 50 keV; (B): The energy of
the incident photon beam is 150 keV.

short-range, high LET photoelectrons. However, there is no increase of dose in the valley due to the
limited range of the electrons.
At 150 keV, a higher dose in the valley at 100 µm from the peak is observed. This occurs because more
energetic electrons are produced by the NP shell, which are able to reach the valley and contribute to the
dose enhancement. Electrons with energy above 90 keV have a range in water larger than 100 µm, as
shown in Table 4.1, [35].
Fig. 4.4 shows the DER with respect to the distance from the centre of the beam in the µ-phantom, due to
a 3 µm NP shell for 50 keV, 70 keV and 150 keV microbeams. The simulation set-up used is shown in
Fig 3.1.

Table 4.1 CSDA (Continuous Slowing Down Approximation) range of electrons in Ta2O5 and water [35].
Electron Energy
Range in Water
Range in Ta2O5
(keV)
(µm)
(µm)
10
2.5
0.74
20
8.6
2.25
30
17.6
4.4
40
29.2
7.1
50
43.2
10.3
60
59.4
13.9
70
77.6
18.0
80
97.7
22.4
90
119.6
27.2
100
143.1
32.3

Figure 4.4: DER due to a 3 µm NP shell in the centre of the microbeam as a function of distance from the
microbeam centre with selected photon energies.

It can be observed that the DER depends on the energy of the incident beam. For each photon energy, the
DER has a first maximum in the centre of the beam and, for higher photon energies, a second maximum
at the edge of of the beam or in the valley. The position of the second maximum depends on the incident
beam energy and the corresponding kinetic energy distribution of the secondary electrons produced in the
NP, which reach the valley with different LETs.

Considering the two extreme cases, the 50 keV photon beam has the highest DER in the MRT peak, while
the 150 keV photon beam has the maximum DER in the valley. In the first case, secondary electrons
originated in the NP have lower energies, therefore they contribute to the DER closer to the NP (the
maximum distance which can be travelled in water is 40 µm, Table 4.1). In the second case, secondary
electrons have more kinetic energy, therefore travel longer distances and deposit energy in the valley
because of their higher LET in this region.

A 70 keV microbeam targeting the K-edge of Ta2O5 (see Figure 4.2), produces a lower DER than 50 keV
and 150 keV beams in the peak and in the valley, respectively. This again is explained by the kinetic
energy distribution of the secondary electrons, which produce a maximum in DER at the edge of the
beam.

The effect of increasing the NP shell thickness, when the shell is present in the peak, results in an increase
of the DER, as indicated by Fig. 4.5 and shown in Figure 4.5.

Figure 4.5: DER dependence on energy and NP shell thickness as a function of distance from the centre
of the microbeam.

The DER increases with growing shell thickness, and this is also energy dependent. There is a (125 ±
10)% increase in the valley dose from a 1 µm to 3 µm NP shell with 150 keV beam, in contrast to 0%
DER increase for the 50 keV beam. The rise in valley %DER with increasing shell thickness is due to the
increase surface-to-volume ratio of the NP congregate.
The peak DER is largest with the lower energy beam, however, increasing the NP thickness results in a
less efficient increase in the DER for 50 keV with respect to the 150 keV beam. This is because the NP
shell is more likely to absorb the higher LET electrons produced by the low energy beam.

4.2 Dose enhancement when the nanoparticle is set in the microbeam valley
Fig. 4.6 shows the DER obtained by moving the NP shell from the beam centre to other positions in or
out of the microbeam. These positions are labelled in Fig. 4.6 as defined in Fig. 3.2. As expected, the NP
shell produces dose enhancement in any position where it is located. The DER depends strongly on the
energy of the incident beam.

(A)

(B)

Figure 4.6: DER to cell population with NP shell located at various locations in the peak (P1), edge of
beam (P2), mid-valley (P3) and valley (P4) as in Fig 3.2, and exposed to 50 keV (A), 150 keV (B)
microbeam.

A 50 keV microbeam tends to produce highly localised dose enhancement, with DER values reaching 52
at maximum. In particular, the dose enhancement is limited to the cell nucleus that the NP cluster
surrounds and the closest neighbouring cell nuclei. Even if a DER of approximately 52 is observed in the
valley, the dose in this region is low. For example the dose calculated in the valley with NPs, at 100 µm
distance from the centre of the peak is (0.17 ± 0.08)×10-11 Gy and (1.5 ± 0.1)×10-11 Gy per incident
photon, for 50 and 150 keV photon beam, respectively.

With a 150 keV beam, lower DER values are observed overall when compared to a 50 keV beam,
however the maximum dose enhancement occurs at greater distances from the NP shell (with DER up to
17). The highest DER in the valley is observed with the NP shell set in the MRT peak, and the DER
reduces when the NP is set at larger distances from the beam centre.

4.3. MRT dose enhancement in a homogeneous solution of nanoparticles
Fig. 4.7 and 4.8 show the dose per incident photon and the DER, respectively, plotted against the distance
from the beam centre. A shell congregate of 3µm thickness, set in the microbeam peak or valley, was
compared to a corresponding solution of Ta2O5 throughout the cell population. The solution has the same
total concentration of Ta2O5 as the NP shell (shown in Table 3.1). Results are shown for a 50 keV and
150 keV incident photon energy.

When the NPs are distributed in a solution throughout the entire µ-phantom, the dose expectedly has no
dependence on the congregation characteristics of the NP. This is reflected in the results of Fig. 4.7. For a
50 keV photon beam, the NP shell causes a larger dose in the peak than the corresponding homogeneous
distribution because of the more localised dose enhancement in the peak and proximity to a greater
density of NPs. When increasing the distance from the beam centre, the dose produced by the solution
becomes larger than in the NP shell case. This occurs because secondary electrons can be produced
throughout the µ-phantom due to the many NP targets, contributing to the dose locally at the point of
generation. As a result, the DER produced by a NP solution is larger than the DER obtained with the NP
shell located in the microbeam peak (see Fig. 4.8).
When the microbeam energy is lower (below 70 keV), a NP shell located in the valley produces a higher
local DER than a homogeneous NP distribution due to enhanced local emission of high LET electrons
depositing energy locally in the valley.

(A)

(B)

Figure 4.7: Physical dose per incident photon with respect to distance from the centre of the microbeam
for NPs distributed as a 3 µm shell in the peak (A) and in the valley (B), compared to NPs distributed
homogeneously (15.6 mg/mL concentration) with selected incident photon energies (50 and 150 keV).

(A)

(B)

Figure 4.8: DER due to homogeneously distributed NPs (15.6 mg/mL), compared to a 3 µm NP shell in
the microbeam peak (A) and in the valley (B) as a function of distance from the microbeam centre with
selected incident photon energies (50 and 150 keV).

When the microbeam has a higher energy, such as 150 keV, the dose and the DER of a NP shell set in the
peak are higher than the configuration of homogeneous solution. This occurs because the NP shell

produces long-range dose enhancement and the probability of interaction with NPs located in the path of
the incident beam is maximised with respect to the NP solution. When, instead, the NP shell is located in
the valley, the associated dose and DER are similar to the homogeneous solution. This happens because
the microbeam has lower probability of interaction with the NP shell when it is located in the valley.

4.4 MRT peak to valley dose ratio with Ta2O5 nanoparticles
The peak-to-valley dose ratio (PVDR) is often used as an indication of the quality of a MRT treatment
[4]. In this study, we have evaluated the PVDR for the case with and without NPs. Figure 4.9 shows the
PVDR with respect to the photon beam energy without NPs, with NPs homogeneously distributed, and
with the NP shell set in the MRT peak or valley. A shell thickness of 3 µm was selected to obtain higher
DER.

The PVDR was measured for locations P1-4 as shown in Fig. 3.2. For any photon beam energy, the
PVDR is largest and smallest when the NP shell is located in the centre of the beam and in the valley,
respectively as shown in Fig. 4.9. This is due to the interplay between the probability of interaction of the
NPs with the incident beam (which is expectedly greater in the peak), and the kinetic energy spectra of
the secondary electrons produced. Overall, the PVDR decreases when the NP shell is placed further from
the peak with respect to water.

The largest PVDR in water is obtained for lower beam energies, due to the short-range photoelectrons
produced in the peak that do not reach the valley. This indicates the greatest potential for tissue sparing,
with overall low valley doses relative to the peak. There is also highly localised dose enhancement
obtained at low beam energies with NP shells, as shown in Fig. 4.6A. Therefore, the PVDR is larger than
the one calculated for water when the NP is located in the peak, and smaller when the NP shell is located
in the valley.
When instead the NP shell is set in the valley, the PVDR is always lower with respect to the case of a
homogeneous solution, except at 150 keV, where instead the PVDRs are similar.
The PVDR calculated with the NP distributed homogeneously was found to always be equal to, or less
than the PVDR calculated in water without NPs, in agreement with Martinez-Rovira et al. [5]. This
occurs because secondary electrons can be produced in the NP material located throughout the entire µphantom, including the valley, and results in a reduction in the PVDR.
The PVDR calculated with the NP solution is therefore always lower than the PVDR calculated with the
NP shell set in the peak, for any energy of the incident photon beam.

These results emphasize how the congregation properties of NPs play a crucial role in determining the
PVDR.

Figure 4.9: PVDR with respect to the photon beam energy, calculated in water without NP (crosses), with
a NP homogeneous solution (black circles) and with a 3 µm NP shell set in the centre of the MRT peak or
valley (diamonds).

5. Discussion and conclusion
This study investigated the physical dose enhancement produced by Ta2O5 NP shells in MRT using a
simplified configuration, where one single NP congregation was located in different positions in the
MRT peak and valley, and compared to homogeneously distributed NPs. This study showed that NP
dose enhancement for SMART is highly dependent on the NP congregation properties, location of
congregations with respect to the beam peak, and photon energy.

The NP dose enhancement was found to increase with the NP shell thickness because of the higher
probability of generating secondary photoelectrons, and was found to be dependent on the energy of the
incident photon beam, as expected. In the case of a photon beam below 70 keV, the DER is mainly
localised to the NPs, and in particular the cell nucleus surrounded by the NP shell and in the adjacent cell
nuclei. When the photon beam energy increases, there are long-range effects, producing significant dose
enhancement at some distance from the NP, due to the greater range of secondary electrons.

The DER is maximised for lower photon energies because of the increase in the photoelectric effect
cross-section. The maximum DER obtained with a 50 keV photon beam is approximately 45 when the

NP is located in the MRT peak. With the NP shell located in the valley, the maximum DER was similar
at 52. With the NP shell is located in the valley, the DER in the valley is generally much higher with low
energy beams because of the localised energy deposition. As a result, the PVDR has its minimum in this
configuration, and only approaches the PVDR without NPs when the beam energy increases.

Overall, the NP shell proved to be useful in enhancing the dose to the population of cells over a large
range of beam energies when located either in the MRT peak or in the valley. A homogeneous NP
solution showed a less variable DER throughout the µ-phantom and across all microbeam energies with
respect to the NP shell, as expected, because of the uniform distribution of NPs in the medium. The NP
homogeneous solution produces a lower PVDR than the case without NPs, across all energies.
Table 5.1 summarises the doses in the peak and valley for a set of NP congregation properties and
energies. These results demonstrate that the NP distribution properties are crucial in determining the
dose enhancement ratio and PVDR, and therefore must be taken into account to optimise the MRT
treatment with NPs. The highest valley dose is produced with a NP shell in the valley at low energies.
This is followed by 150 keV beam incident on a NP shell to produce significant NP dose enhancement,
independently from the location of the NP shell with respect to the microbeam. The NP homogeneous
distribution tends to increase the valley dose at least two-fold for any MRT energy considered.

Table 5.1 Summary of physical dose per incident photon (Gy) due to microbeam energies of 50 keV and
150 keV, comparing NP shell and NP solution results in the peak and valley. The grey cells indicate the
configurations with the largest dose in the peak and in the valley of the microbeam.
50 keV

150 keV

Peak

Valley

Peak

Valley

No NP

(5.59 ± 0.06)×10-9

(1.7 ± 0.8)×10-12

(11.71 ± 0.07)×10-9

(15 ± 1)×10-12

3 µm NP shell
at P1
3 µm NP shell
at P4
15.6 mg/mL
homogeneous

(251.5 ± 0.2)×10-9

(2.8 ± 0.6)×10-12

(69.6 ± 0.1)×10-9

(55 ± 4)×10-12

(5.59 ± 0.06)×10-9

(89 ± 5)×10-12

(11.66 ± 0.06)×10-9

(38 ± 4)×10-12

(11.80 ± 0.09)×10-9

(3.3 ± 0.6)×10-12

(12.59 ± 0.06)×10-9

(30 ± 3)×10-12

The results of this study indicate that both the NP distribution and microbeam energy must be considered
for efficient NP dose enhancement. MRT beams with energy range below the K-edge of Ta (~70 keV),

may be adopted to reduce collateral effects to healthy tissues, due to the largest PVDR in water.
Furthermore, the significant local dose enhancements produced by selective NP shells in tumour cells via
the increased production of higher LET electrons, give good prognosis for tumour control. With a
selective internalisation in the tumour cells, higher target doses may be delivered to the tumour, which is
beneficial for effective treatment of radioresistant cancers [5,16,17].

Another possible solution is to instead adopt a higher energy photon beam (above ~ 100 keV), which
reduces the PVDR with NPs both homogeneously distributed and with NP shells. This solution may be
more beneficial to achieve a better coverage of the tumour, particularly for homogeneous NP
distributions, while eventually reducing the overall dose administered to the patient.

In order to further investigate the optimal energy of the photon beam, future simulation work will
investigate the DER and PVDR in a more realistic scenario in terms of shell distribution throughout the
entire cell population. The effect of multiple microbeams will be investigated as well as the effect of
different peak-to-peak spacing and beam widths. The simulation study will be integrated with
radiobiological measurements at the AS using low microbeam energies to quantify NP sensitisation.
Furthermore, the selectivity of internalisation of NP shells will be investigated.
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